Funding for this research was provided by:
Gynecologic Cancers Research Foundation (n/a)
United Foundation for China's Health (n/a)
Received: 29 July 2020
Accepted: 29 September 2020
First Online: 22 October 2020
Ethics approval and consent to participate
: IRB approval was obtained prior the performance of the study from the United Family Hospitals’ Investigational review board. Approval number UFHIRB: E2019–003.
: The authors consent to publish.
: Andrew Goldstein: President of the Gynecologic Cancers Research Foundation: a non-profit 501(c)3 corporation. Received research funding from the Gynecologic Cancers Research Foundation.Yang Lei: none to report.Lena Goldstein: none to report.Amelia Goldstein: none to report.Qiao Xu Bai: none to report.Juan Felix: none to report.Roberta Lipson: Director, United Foundation for China’s Health, a non-profit 501(c)3 corporation. Shareholder in MobileODT.Maria Demarco, Mark Schiffman, Didem Egemen, Kanan Desai: NCI has received cervical screening supplies and results at no cost from several companies (Roche, BD, Qiagen, MobileODT) for independent evaluations of test performance.Sarah Bedell: none to report.Janet Gersten: none to report.Gail Goldstein: Is a board member of the Gynecologic Cancers Research Foundation: a non-profit 501(c)3 corporation.Karen O’Keefe: none to report.Casey O’Keefe: none to report.Tierney O’Keefe: none to report.Cathy Sebag: Was an employee of MobileODT during the data collection.Lior Lobel: Was an employee of MobileODT during the data collection.Anna Zhao: employee, United Foundation for China’s Health, a non-profit 501(c)3 corporation.Yan Ling Lu: none to report.